Difference between revisions of "NET of unknown primary"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br>" to "font-size:300%"> Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br>") |
Warner-admin (talk | contribs) m (Text replacement - "Just 10 days left" to "Just 9 days left") |
||
| Line 1: | Line 1: | ||
{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | {|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | ||
| | | | ||
| − | <span style="font-family:Arial; font-size:300%"> Just | + | <span style="font-family:Arial; font-size:300%"> Just 9 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br> |
'''Link:''' http://j.mp/2BlBaoQ | '''Link:''' http://j.mp/2BlBaoQ | ||
</span> | </span> | ||
Revision as of 13:49, 23 January 2018
|
Just 9 days left to fill out a survey on how we can make HemOnc.org better and more useful. |
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
0 regimens on this page
0 variants on this page
|
Guidelines
ESMO
- Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) PubMed
NCCN
All lines of therapy
- Poorly differentiated or small cell tumors can be treated with small cell lung cancer regimens.
- Moderate to well-differentiated neuroendocrine tumors can be treated with regimens for neuroendocrine tumors.